Selective Dopamine D3 Ligand for Neurological Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of highly selective dopamine D3 receptor ligands in clinical and commercial medications, which hinders investigations on the distribution and function of dopamine D3 receptors and the pathogenesis of associated neurological diseases.
Innovation Solution
A novel dopamine D3 receptor-selective ligand with a specific major structure, comprising a urea group located at certain positions on a naphthalene, quinoline, or isoquinoline ring, is developed. This ligand has high affinity, specificity, and functional selectivity, selectively mediating signaling pathways downstream of the D3 receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If commonly used antipsychotic drugs are administered, then D2 receptor activation occurs, but selectivity between D2 and D3 receptors is low causing side effects
Solution Approach 1:
The patent applies local quality by introducing specific substituents (R1 and R2) at defined positions on the aromatic ring of the arylpiperazine structure. These local modifications create steric hindrance and electronic effects that selectively favor D3 receptor binding over D2 receptor binding, thereby achieving high receptor selectivity while minimizing side effects associated with non-selective D2 activation
Solution Approach 2:
The patent employs parameter changes by systematically varying the substituent parameters (different halogen atoms, hydroxyl groups, and their positions) on the arylpiperazine core structure. These parameter modifications alter the molecular properties such as lipophilicity, steric bulk, and electronic distribution, which collectively enhance D3 receptor selectivity and reduce off-target effects
2Reliability
If D2 receptor inhibitors are used to treat schizophrenia, then positive symptoms are addressed, but extrapyramidal symptoms occur due to low D3 receptor selectivity
Solution Approach 1:
The patent applies local quality by introducing specific substituents (R1 and R2) at defined positions on the aromatic ring of the arylpiperazine structure. These local modifications create steric hindrance and electronic effects that selectively favor D3 receptor binding over D2 receptor binding, thereby achieving high receptor selectivity while minimizing side effects associated with non-selective D2 activation
3Reliability
If there is a lack of highly selective D3 receptor ligands, then research on D3 receptor function is hindered, but developing such ligands requires complex synthesis
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional segments: the arylpiperazine core (which provides D3 receptor affinity), the aromatic substituent (which provides selectivity), and the hydroxyl group (which provides additional binding interactions). This modular structure allows for systematic optimization of each segment independently while maintaining overall D3 selectivity
Solution Approach 2:
The patent employs universality by designing a core arylpiperazine structure that serves multiple functions: providing baseline D3 receptor affinity, enabling selective binding through aromatic substituents, and allowing for metabolic stability. This multi-functional core structure simplifies the overall synthesis by reducing the need for complex multi-step transformations
Data Source
AI summary
The present invention provides a novel ligand for the dopamine D3 receptor and a preparation method therefor. The compound, and a pharmaceutically acceptable salt and a pharmaceutical composition or a pharmaceutical preparation thereof are used for the treatment and prevention of schizophrenia, neurodegenerative diseases, particularly Parkinson's disease, drug dependence, drug addiction, anxiety, depression, etc. The novel ligand of the dopamine D3 receptor features a high affinity, a high specificity, and a high functional selectivity. The compound and the pharmaceutically acceptable salt and the pharmaceutical composition or the pharmaceutical preparation thereof can be used to study the distribution and function of dopamine D2 subtype receptors and mechanism of diseases associated with dysfunction of dopamine D2-like receptors, and can also be used for the disease modification of hyperprolactinemia, extrapyramidal symptoms, and levodopa-associated movement disorder or dyskinesia.